VEGFA and glioblastoma: Considering the crosstalk between the endoglin and VEGF pathways, one might hypothesize that, in recurrent GBM patients highly expressing CD105, combined TRC105/anti-VEGF therapy could be a potential therapeutic strategy, reserving anti-angiogenic monotherapy for recurrent GBM patients with low levels of CD105 expression.